Skip to main content

Table 3 Laboratory values of patients with coagulopathic endotype at day 7 by arm of treatment

From: Transitions of blood immune endotypes and improved outcome by anakinra in COVID-19 pneumonia: an analysis of the SAVE-MORE randomized controlled trial

Laboratory values,

median (Q1–Q3)

SoC + Placebo (Ν = 34)

SoC + Anakinra (Ν = 54)

p

White blood cells, /mm3

8800 (7400 to 12,480)

8580 (6820 to 10,185)

0.684

Lymphocytes, /mm3

720 (535 to 1260)

1060 (735 to 1560)

0.003

Platelets, /mm3

314,000 (247,500 to 422,500)

363,000 (307,500 to 466,500)

0.026

C-reactive protein, mg/l

15.2 (6.8 to 51.6)

6.5 (2.5 to 27.9)

0.001

Interleukin-6, pg/ml

14.4 (3.4 to 59.2)

5.1 (1.4 to 14.7)

0.016

Ferritin, ng/ml

585.8 (355.9 to 889.0)

490.9 (247.2 to 825.8)

0.373

D-dimers, mg/l

0.72 (0.38 to 1.62)

0.81 (0.37 to 1.74)

0.910

Serum soluble uPAR, ng/ml

8.0 (6.3 to 12.1)

6.5 (4.7 to 8.4)

 < 0.001

% Change of lymphocytes at day 7 from baseline

 − 17.7 (− 71.8 to 13.3)

 − 50.1 (− 97.5 to − 13.1)

0.020

% Change of C-reactive protein at day 7 from baseline

 − 71.8 (− 90.9 to − 1.5)

 − 91.9 (− 95.6 to − 67.2)

0.002

% Change of interleukin-6 at day 7 from baseline

 − 16.8 (− 71.9 to 77.8)

 − 49.1 (− 78.3 to 22.2)

0.136

% Change of ferritin at day 7 from baseline

 − 8.0 (− 28.7 to 13.1)

 − 32.8 (− 47.9 to − 10.4)

0.010

% Change of D-dimers at day 7 from baseline

32.1 (− 5.0 to 216.7)

6.6 (− 22.1 to 101.6)

0.208

% Change of suPAR at day 7 from baseline

20.3 (− 4.6 to 38.6)

 − 17.4 (-43.2 to 9.1)

 < 0.0001

  1. P-values of statistical significance are marked in bold
  2. SoC standard of care, Q quartile, uPAR urokinase plasminogen activator receptor